Can New York Innovate Away its Public Transit Woes?

With a whopping average of 56 hours a year of delay per commuter, New York recently earned the number one spot for worst traffic congestion in Texas A&M’s Urban Mobility Report. One potential solution in clearing up all the blockage in the Big Apple is getting more people into public transit.

But for the MTA, increasing consistent public transit ridership isn’t a quick fix. In fact, it is a challenge of several different factors, including improving infrastructure quality, maintaining ridership, and incentivizing new users to ride public transit.

To discuss some of the strategies used to combat these challenges as well as overall trends observed in US public transit, Daniel Litwin, Voice of B2B, invited Mark Prommel, Partner & Design Director at Brooklyn-based product design firm, PENSA, to this episode of MarketScale TV.

The two explored what tech investments seem to have a good track record in New York’s public transit approach, as well as where the Federal CARES Relief money would be the most effective.

With 23 years of experience in NYC, Prommel explains that the power of the public transit system is in the interconnected communication between above-ground and underground systems. However, Prommel warns that none of that can start to take place until the backend infrastructure of the system is modernized.

“There’s an underlying foundation that has to be addressed. That’s really where any money has to be targeted at this point,” Prommel said.

They also explore public transit trends on a national scale, such as what professionals should be pushing for to meet these challenges, especially as the Biden administration funnels billions towards transportation revitalization, as well as how feasible strategies such as general promotions or free transfers between public transit are for incentivizing ridership in the long term.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More